News
AVCNF
0.105
NaN%
--
Weekly Report: what happened at AVCNF last week (0406-0410)?
Weekly Report · 1d ago
Avicanna Inc Earnings Call Highlights Margin Turnaround
TipRanks · 6d ago
ThreeD Capital sells 977,000 Avicanna shares for $164,497, cuts stake to 12.7%
Reuters · 6d ago
Avicanna Strengthens Board as It Targets Global Cannabinoid Growth
TipRanks · 04/06 22:09
Avicanna appoints Ozgur Kilic to board after John McVicar resigns
Reuters · 04/06 21:31
AVICANNA ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
Reuters · 04/06 21:30
Weekly Report: what happened at AVCNF last week (0330-0403)?
Weekly Report · 04/06 09:43
Avicanna Inc. reports FY results
Seeking Alpha · 04/02 13:04
Avicanna Nears Profitability as Margins Improve and Clinical, Commercial Platforms Advance
TipRanks · 04/01 14:34
Avicanna FY25 adjusted EBITDA narrows to $(0.29) million; revenue totals $25.48 million
Reuters · 04/01 11:30
AVICANNA INC - FY2025 GROSS MARGIN EXPANDS TO 53%; GROSS PROFIT TOTALS $13.4 MLN
Reuters · 04/01 11:30
Weekly Report: what happened at AVCNF last week (0323-0327)?
Weekly Report · 03/30 09:43
Avicanna’s SMGH Unit Makes First CBG Flower Export to Australia, Expanding Global Footprint
TipRanks · 03/26 12:36
Avicanna subsidiary Santa Marta Golden Hemp completes first commercial export of CBG-dominant cannabis flower to Australia; SMGH market reach grows to 21 markets
Reuters · 03/26 11:32
Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
Barchart · 03/26 06:30
Weekly Report: what happened at AVCNF last week (0316-0320)?
Weekly Report · 03/23 09:41
Avicanna Backs University of Calgary Trial to Map Optimal Oral THC Dosing
TipRanks · 03/16 12:08
Avicanna sponsors University of Calgary THC dose finding trial
TipRanks · 03/16 11:41
Avicanna sponsors University of Calgary Phase I oral THC dose-finding trial in 24 healthy adults
Reuters · 03/16 11:30
AVICANNA ANNOUNCES SPONSORSHIP OF UNIVERSITY OF CALGARY THC DOSE FINDING CLINICAL TRIAL
Reuters · 03/16 11:30
More
Webull provides a variety of real-time AVCNF stock news. You can receive the latest news about Avicanna through multiple platforms. This information may help you make smarter investment decisions.
About AVCNF
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.